# Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

> **NCT04437160** · PHASE2 · RECRUITING · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 286 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Epirubicin or Pirarubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04437160
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-01
- **Primary completion:** 2026-01
- **Final completion:** 2027-12
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04437160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04437160, "Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04437160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*